Shareholders that lost money on MacroGenics, Inc. Urged to Join Class Action Contact Levi Korsinsky to Learn More
MGNX Stock | USD 3.50 0.11 3.24% |
Slightly above 58% of all MacroGenics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding MacroGenics suggests that some traders are interested. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
MacroGenics |
NEW YORK, July 31, 2024 -- Levi Korsinsky, LLP notifies investors in MacroGenics, Inc. of a class action securities lawsuit. CLASS
Read at benzinga.com
MacroGenics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards MacroGenics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MacroGenics Fundamental Analysis
We analyze MacroGenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MacroGenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MacroGenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
MacroGenics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
MacroGenics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MacroGenics stock to make a market-neutral strategy. Peer analysis of MacroGenics could also be used in its relative valuation, which is a method of valuing MacroGenics by comparing valuation metrics with similar companies.
Peers
MacroGenics Related Equities
CCCC | C4 Therapeutics | 13.33 | ||||
MLYS | Mineralys Therapeutics, | 8.10 | ||||
GLUE | Monte Rosa | 6.57 | ||||
IPSC | Century Therapeutics | 6.29 | ||||
CGEM | Cullinan Oncology | 4.98 | ||||
ZNTL | Zentalis Pharmaceuticals | 4.79 | ||||
TYRA | Tyra Biosciences | 3.69 | ||||
INZY | Inozyme Pharma | 3.63 | ||||
EWTX | Edgewise Therapeutics | 3.23 | ||||
DAWN | Day One | 2.15 | ||||
PEPG | PepGen | 1.42 | ||||
SNDX | Syndax Pharmaceuticals | 1.25 | ||||
PTGX | Protagonist Therapeutics | 0.91 | ||||
ANTX | AN2 Therapeutics | 0.69 | ||||
MOLN | Molecular Partners | 1.55 | ||||
KZR | Kezar Life | 2.16 | ||||
NKTX | Nkarta | 2.27 | ||||
PHVS | Pharvaris | 2.31 | ||||
PMVP | Pmv Pharmaceuticals | 5.36 |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.